# EDGAR Filing Document

**Accession Number:** 0001671927
**File Stem:** 0001779466-26-000002
**Filing Date:** 2026-2
**Character Count:** 7795
**Document Hash:** 134de6b323dbd10b440c2bb1a2b38997
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001779466-26-000002.hdr.sgml**: 20260219

**ACCESSION NUMBER**: 0001779466-26-000002

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260217

**FILED AS OF DATE**: 20260219

**DATE AS OF CHANGE**: 20260219

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** GOLL JOHN
- **CENTRAL INDEX KEY:** 0001779466

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39992
- **FILM NUMBER:** 26655457

**MAIL ADDRESS:**
- **STREET 1:** 10 FINDERNE AVENUE
- **CITY:** BRIDGEWATER
- **STATE:** NJ
- **ZIP:** 08807
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Immunocore Holdings plc
- **CENTRAL INDEX KEY:** 0001671927
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 90 PARK DRIVE
- **STREET 2:** MILTON PARK, ABINGDON
- **CITY:** OXFORDSHIRE
- **STATE:** X0
- **ZIP:** OX14 4RY
- **BUSINESS PHONE:** 01235 5430281

**MAIL ADDRESS:**
- **STREET 1:** 90 PARK DRIVE
- **STREET 2:** MILTON PARK, ABINGDON
- **CITY:** OXFORDSHIRE
- **STATE:** X0
- **ZIP:** OX14 4RY

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Immunocore Ltd
- **DATE OF NAME CHANGE:** 20160412

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>GOLL JOHN<br><sub>(Last) (First) (Middle)</sub><br>C/O IMMUNOCORE HOLDINGS PLC<br>92 PARK DRIVE, MILTON PARK<br><sub>(Street)</sub><br>ABINGDON, OXFORDSHIRE, X0 OX14 4RY<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-17 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_SVP, FINANCE & CAO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Immunocore Holdings plc [ IMCR ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Ordinary Shares<sup>(1)</sup> | 2026-02-17 |  | M |  | 1351 | A | $0 | 1351 | D |  |
| Ordinary Shares<sup>(1)</sup> | 2026-02-18 |  | S |  | 698<sup>(2)</sup> | D | 32.35<sup>(3)</sup> | 653 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Share Units | <sup>(4)</sup> | 2026-02-17 |  | M |  |  | 1351 | <sup>(5)</sup> | <sup>(5)</sup> | Ordinary Shares<sup>(1)</sup> | 1351 | $0 | 4054 | D |  |
| Restricted Share Units | <sup>(4)</sup> | 2026-02-17 |  | A |  | 7411 |  | <sup>(6)</sup> | <sup>(6)</sup> | Ordinary Shares<sup>(1)</sup> | 7411 | $0 | 7411 | D |  |
| Employee Share Option (Right to Buy) | $32.38 | 2026-02-17 |  | A |  | 21252 |  | <sup>(7)</sup> | 2036-02-16 | Ordinary Shares<sup>(1)</sup> | 21252 | $0 | 21252 | D |  |

---

### Footnotes:

(1) Ordinary Shares may be represented by American Depositary Shares.  Each American Depositary Share represents one Ordinary Share.

(2) The shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted share units ("RSUs") .

(3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.18 to $32.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(4) Each RSU represents a contingent right to receive one Ordinary Share.

(5) On February 17, 2025, the Reporting Person was granted 5,405 RSUs, vesting in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date.

(6) The RSUs vest in four equal annual installments beginning February 17, 2027, subject to the Reporting Person's continuous service through each such vesting date.

(7) 25% of the shares subject to the option award shall vest on February 17, 2027, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

**Signature:** /s/ Lily Hepworth, Attorney-in-Fact  
**Date:** 2026-02-19

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**